Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Views & Analysis Value for money of Health Technology Assessment Health Technology Assessment (HTA), despite the many definitions in use, has become almost synonymous with value for money (VfM). But just what is the value for money of HTA itself?
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
